Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.36 |
| ▸ | USP5 | P45974 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14563156 | 0.84 | TRPA1 (0.50) | FFAR2TRPA1RIPK1 | |
| SCHEMBL2351859 | 0.82 | FFAR2 (0.43) | FFAR2TRPA1 | |
| SCHEMBL20835375 | 0.82 | RIPK1 (0.44) | TRPA1RIPK1 | |
| SCHEMBL4083074 | 0.81 | FFAR2 (0.43) | FFAR2RIPK1USP5HDAC6CNR1 | |
| SCHEMBL4501609 | 0.80 | FFAR2 (0.44) | FFAR2TRPA1USP5HDAC6 | |
| SCHEMBL2584676 | 0.80 | FFAR2 (0.44) | FFAR2TRPA1USP5HDAC6 | |
| SCHEMBL30871631 | 0.78 | CYP3A4 (0.38) | TRPA1 | |
| SCHEMBL30871678 | 0.78 | CYP3A4 (0.38) | TRPA1 | |
| SCHEMBL2587832 | 0.78 | FFAR2 (0.42) | FFAR2TRPA1 | |
| SCHEMBL4512466 | 0.78 | FFAR2 (0.42) | FFAR2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | FFAR2 1593/4885TRPA1 441/4885RIPK1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.